Durable treatment response to Trastuzumab deruxtecan in two patients with recurrent grade III anaplastic ependymoma
Dietmar Krex, Irina A. Kerle, Arne Grey, Stephanie Pleißner, Stephan Richter, Christoph Heining, Stefan Fröhling, Hanno Glimm, Martin Bornhäuser, Gunnar Folprecht, Andy Göbel, Cornelia S. Link-Rachner · 2026
Read Durable treatment response to Trastuzumab deruxtecan in two patients with recurrent grade III anaplastic ependymoma by Dietmar Krex, Irina A. Kerle, Arne Grey, Stephanie Pleißner, Stephan Richter, Christoph Heining, Stefan Fröhling, Hanno Glimm, Martin Bornhäuser, Gunnar Folprecht, Andy Göbel, Cornelia S. Link-Rachner (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13646213.txt.
Description
Dietmar Krex and co-authors report two 2026 cases of a rare brain tumor treated with a targeted drug. The tumor, anaplastic ependymoma, is aggressive and has few drug options once it returns. Both patients had repeated recurrences and had used up standard local and drug treatments. Deep molecular profiling of their tumors showed the HER2 growth signal switched on. That finding led the team to try a drug that carries chemotherapy straight to HER2 marked cells, used off label.
The first patient's disease steadied and stayed controlled for twenty six months, after an early mixed scan picture. The second patient first worsened on a different drug pair, then steadied on the new drug for fourteen months at last check. Side effects on blood counts and the liver were handled with support, dose changes, and pauses. The authors present the cases as a case for molecular guided choices.
Catalog record
| CREATOR | Dietmar Krex, Irina A. Kerle, Arne Grey, Stephanie Pleißner, Stephan Richter, Christoph Heining, Stefan Fröhling, Hanno Glimm, Martin Bornhäuser, Gunnar Folprecht, Andy Göbel, Cornelia S. Link-Rachner |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 17 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |